Shanghai - Delayed Quote CNY

Changchun BCHT Biotechnology Co. (688276.SS)

20.90
+0.05
+(0.24%)
As of 2:22:08 PM GMT+8. Market Open.
Loading Chart for 688276.SS
  • Previous Close 20.85
  • Open 20.88
  • Bid 20.89 x --
  • Ask 20.88 x --
  • Day's Range 20.79 - 20.97
  • 52 Week Range 20.19 - 39.09
  • Volume 933,636
  • Avg. Volume 2,725,276
  • Market Cap (intraday) 8.645B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 50.98
  • EPS (TTM) 0.41
  • Earnings Date --
  • Forward Dividend & Yield 0.15 (0.72%)
  • Ex-Dividend Date May 24, 2024
  • 1y Target Est --

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. The company's products include live herpes zoster vaccine; live varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and Rabies vaccine (vero cell) for humans. Changchun BCHT Biotechnology Co. Ltd. was founded in 2004 and is based in Changchun, China.

www.bchtpharm.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688276.SS

View More

Performance Overview: 688276.SS

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688276.SS
16.77%
SSE Composite Index (000001.SS)
0.44%

1-Year Return

688276.SS
45.02%
SSE Composite Index (000001.SS)
7.82%

3-Year Return

688276.SS
47.39%
SSE Composite Index (000001.SS)
9.53%

5-Year Return

688276.SS
82.58%
SSE Composite Index (000001.SS)
17.37%

Compare To: 688276.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688276.SS

View More

Valuation Measures

As of 5/15/2025
  • Market Cap

    8.62B

  • Enterprise Value

    8.58B

  • Trailing P/E

    50.85

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.69

  • Price/Book (mrq)

    2.05

  • Enterprise Value/Revenue

    7.65

  • Enterprise Value/EBITDA

    45.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.40%

  • Return on Assets (ttm)

    2.84%

  • Return on Equity (ttm)

    4.16%

  • Revenue (ttm)

    1.12B

  • Net Income Avi to Common (ttm)

    172.59M

  • Diluted EPS (ttm)

    0.41

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    224.1M

  • Total Debt/Equity (mrq)

    4.16%

  • Levered Free Cash Flow (ttm)

    -22.13M

Research Analysis: 688276.SS

View More

People Also Watch